

derivatives of said binders, containing the amino acid sequence Ala-Arg-Asn-Arg-Asn and/or Ala-Arg-Asn-Gly-Asn.

25. Use of the method according to claims 1 to 20 to determine concentrations of clinically related substances in samples of biological material from living organisms in need thereof.

26. Kit for determination of concentration of one or more analytes in a test sample or an aliquot of a test sample of complex biological fluid, characterized in comprising one or more containers, wherein the container(s) or compartment of the container(s) contains one single reagent, preferably in the fluidal state according to any of the claims 21-24, and wherein the reagent comprises one or more fluorescence-labelled specific binding molecules towards the analyte(s) to be measured, or a fluorescence-labelled analogue or a fluorescents fragment or a eluorescent derivative of said analyte(s), as well as device for obtaining the exact volume(s) of the complex biological fluid to be tested and that is needed in order to perform the method adequately.

#### MARKED-UP CLAIMS

5. A method according to [any of the] claim[s] 1 [to 4], characterized by using a reagent comprising fluorescent binding molecules with specific affinity for one analyte, or comprising fluorescent analogues of, or fluorescent fragments of, or fluorescent derivatives of one analyte only.

6. A method according to [any of the] claim[s] 1 [to 5], characterized by the use of a reagent comprising different fluorescent moieties covalently bound to different binding molecules with different specific affinities.

7. A method according to [any of the] claim[s] 1 [to 6], characterized by the use of a reagent comprising one or more peptides or derivatives of peptides with specific binding affinity for an analyte, said binding peptides having a fluorescent residue covalently linked and being constituted by less than 30 amino acids.
10. A method according to [any of the] claim[s] 1 [to 9], characterized by the use of a reagent comprising peptides or derivatives of peptides containing amino acid sequence Ala-Arg-Asn-Arg-Asn or Ala-Arg-Asn-Gly-Asn for quantitation of C-reactive protein.
11. A method according to [any of the] claim[s] 1 [to 10], characterized by the use of a reagent with fluorescent residues with maximum coefficient of absorption at a wavelength above 640 nm.
12. A method according to [any of the] claim[s] 1 [to 11], characterized by the use of a reagent comprising cell lysing substances or anticoagulants or detergents.
13. A method according to [any of the] claim[s] 1 [to 12], characterized by the use of a reagent comprising one or more fluorescent moieties selected from the group consisting of fluoresceine, Texas Red, Cy5, other Cy dye, FluorLink substance, other yanin derivatives, Rhodamin, Methyl Rhodamin, Biodypi 630/650-X/MeOH, Biodypi 650/655-X/MeOH, Biodypi FL/MeOH, Biodypi R6G/MeOH, Biodypi TMR-XMeOH Biodypi TR-X/MeOH or other substance from the Biodypi group of substances, Alexa Fluor Dyes of different wavelengths, Ruthenium ligand complexes, lanthanoid elements such as Europium, Samarium or Terbium complex bound to a chelating ligand like DTPA, EDTA or N1.
14. A method according to [any of the] claim[s] 1 [to 13], characterized by that the polarization of the emitted light is measured as a function of time, either as a continuous

kinetic reading or a reading of the change in polarization of the emitted light between two or more time points, or as a measurement of the polarization of the emitted light after a defined point of time.

15. A method according to [any of the] claim[s] 1 [to 14], characterized by that sample material or aliquot of the sample material is constituted by a biological material, or a dilution or an extract or being dissolved from or being filtrated from the said biological material.

16. A method according to [any of the] claim[s] 1 [to 15], characterized by that sample material or aliquot of the sample material is constituted by blood, or blood serum, or blood plasma, or blood cells, or lysate from blood or blood cells, or urine, or cerebrospinal fluid, or tear liquid, or sputum, or semen, or plasma, or semen or material aspirated from the gastro-intestinal tract or feces, or extract or filtrate or suspension of feces, or plant material or extracts thereof, or dissolved plant material or filtrate thereof.

17. A method according to [any of the] claim[s] 1 [to 16], characterized by the use of standards or calibrators comprising known concentrations of the analyte or the analytes, and furthermore wherin the concentration or concentrations of said analyte or analytes in unknown samples is calculated by interpolation of the values obtained from the unknown samples of the standard curve obtained from said known standards or calibrators.

18. A method according to [any of the] claim[s] 1 [to 17], characterized by the use of a standard curve stored in an artificial memory, optionally connected to the fluorescent polarization instrument in use.

19. A method according to [any of the] claim[s] 1 [to 18], characterized by the use of temperature correction algorithms, either generated empirically or theoretically, to compensate for differences in fluorescence polarization caused by differences in temperature at different time of measurements of standards and unknown samples, or between standards, or between unknown samples.
20. A method according to [any of the] claim[s] 1 [to 19], characterized by being provided in concentrated or dry form, to be diluted or reconstituted before use, the said reagent being provided divided between different compartments for combination into one reagent prior to use.
21. A reagent for the performance of the method according to [any of the] claim[s] 1 [to 20], characterized in that said reagent comprise at least one type of binding molecule with specific affinity for one or more of the said analytes, and said reagent furthermore comprises fluorescent moieties covalently linked to the said binding molecules or fluorescent analogues of or fluorescent fragments of or fluorescent derivatives of said analyte or analytes.
23. A reagent according to claim[s] 21 [to 22], characterized in comprising binding molecules with specific affinity for one or more of the said analytes and optionally with fluorescent moieties with absorption maximum between 600 nm and 1000 nm, preferably exceeding 620 nm, more preferably exceeding 640 nm, covalently linked to the said binding molecules, and said binding molecules being either of peptide or aptamer composition or being synthetic binders, optionally being identified by combinatorial chemistry techniques or phage display or nucleic acid technology.

24. A reagent according to claim[s] 21 [to 23], characterized in being as assay reagent comprising peptide binders or binders of derivatives of peptides, including fluorescent derivatives of said binders, containing the amino acid sequence Ala-Arg-Asn-Arg-Asn and/or Ala-Arg-Asn-Gly-Asn.

25. Use of the method according to claim[s] 1 [to 20] to determine concentrations of clinically related substances in samples of biological material from living organisms in need thereof.

26. Kit for determination of concentration of one or more analytes in a test sample or an aliquot of a test sample of complex biological fluid, characterized in comprising one or more containers, wherein the container(s) or compartment of the container(s) contains one single reagent, preferably in the fluidal state according to [any of the] claim[s] 21[-24], and wherein the reagent comprises one or more fluorescence-labelled spesific binding molecules towards the analyte(s) to be measured, or a fluorescence-labelled analogue or a fluorescents fragment or a eluorescent derivative of said analyte(s), as well as device for obtaining the exact volume(s) of the complex biological fluid to be tested and that is needed in order to perform the method adequately.

REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 5, 6, 7, 10, 11-21 and 23-26.

A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.


If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, John J. Gresens (Reg. No. 33,112), at (612) 371.5265.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: December 21, 2001

By



John J. Gresens  
Reg. No. 33,112

JJG/kjr/jlh